Nature Medicine issues author correction to povorcitinib STOP-HS1 and STOP-HS2 phase 3 trials
Start here
Nature Medicine has published an author correction to the povorcitinib hidradenitis suppurativa STOP-HS1 and STOP-HS2 phase 3 randomized, double-blind, placebo-controlled trials. The correction addresses several errors: the upper limit of baseline disease duration, discontinuation details in the Fig. 1 legend, P value superscripts in Table 2, colors and label placement in Extended Data Fig. 5e and 5f, and row order in Supplementary Table 6A. Both the HTML and PDF versions of the article have been updated to reflect these changes. No further corrections or responses related to the trials are currently noted in the record.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- NatureAuthor Correction: Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials
Nature Medicine has published an author correction to the povorcitinib hidradenitis suppurativa STOP-HS1 and STOP-HS2 phase 3 randomized, double-blind, placebo-controlled trials. The correction fixes the upper limit of baseline disease duration, discontinuation details in the Figure 1 legend, a P value superscript in Table 2, colors and label positions in Extended Data Figures 5e and 5f, and row order in Supplementary Table 6A. The HTML and PDF versions have been updated.
Coverage and heat for this story
Reports so far 1·Heat now 6·Peak heat 10 (Oct 21 08:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.